Comparative Pharmacology
Head-to-head clinical analysis: MEPERIDINE HYDROCHLORIDE versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPERIDINE HYDROCHLORIDE versus QOLIANA.
MEPERIDINE HYDROCHLORIDE vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meperidine is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia. It also has weak serotonergic activity.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
50-150 mg orally or intramuscularly every 3-4 hours as needed for pain. Maximum single dose: 150 mg. Maximum daily dose: 600 mg.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
3-4 hours in normal renal function; prolonged to >12 hours in hepatic impairment (cirrhosis) or renal failure (normeperidine accumulates)
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Renal: 70-80% as metabolites (normeperidine ~20%, meperidinic acid ~50%) and <5% unchanged; biliary/fecal: <10%
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist